Synthio Labs has secured a $5 million seed round to advance its clinical-grade voice AI platform, positioning the company as a foundational technology provider for customer engagement across the life sciences sector. Elevation Capital led the funding with participation from 1984 Ventures, Peak XV Partners, Y Combinator, and several strategic healthcare and AI industry angels.
The San Francisco-based startup is building what it describes as a voice-driven operating system for global pharma, as artificial intelligence increasingly becomes the backbone of customer and patient engagement infrastructure. Synthio Labs aims to streamline how life sciences organizations interact with clinicians and patients, replacing fragmented, manual, and labor-intensive communication processes that cost pharma companies more than $30 billion annually.
Synthio Labs’ platform powers real-time, compliant conversations while enabling field teams, physicians, and patients to access clear and accurate medical information at any time. The company said its technology is especially impactful in chronic care and large patient-support programs, where high drop-off rates and inconsistent communication have long been persistent challenges.
The company’s AI operating system integrates three flagship offerings: Jarvis, the voice AI copilot for field teams; Ather, a multimodal engine enabling omnichannel physician and patient engagement; and Simulation Studio, a research-focused tool that creates digital twins of clinicians and patients to generate strategic insights. Collectively, these capabilities allow commercial and medical teams to automate compliant interactions, capture structured intelligence at scale, and deliver trustworthy, human-grade experiences.
Synthio Labs’ founders, who previously held roles at McKinsey, ZS Associates, Amazon, and Audible, bring expertise across pharma strategy, AI engineering, commercial operations, and generative-AI systems development. The new capital will support engineering and product expansion, global enterprise deployments across the United States and Europe, and deeper relationships with major life sciences clients.
Early customers include several Top 10 pharmaceutical companies and leading D2C healthcare brands. In one example, the company’s voice agent engaged more than 5,000 eczema patients in just 48 hours, demonstrating the platform’s ability to scale personalized outreach at high speed and with high reliability.
Synthio Labs plans to continue building toward a future where AI-powered voice communication becomes a core component of how global pharma teams support clinicians and patients.
KEY QUOTES
“We believe Synthio Labs is defining the next major Customer Engagement infrastructure for Life Sciences. Their Clinical-grade Voice AI platform unifies how pharma communicates – giving field teams a powerful voice companion, and giving physicians and patients instant, trusted, compliant answers 24/7. Pharma’s global Commercial and GTM footprint is a trillion-dollar machine ripe for reinvention, and Synthio has exactly the right team to deliver on this mission.”
Krishna Mehra, AI Partner, Elevation Capital
“Beyond breakthrough medicines, the future of healthcare will depend on how we reach and support every clinician and patient who relies on them.”
Supreet Deshpande, Co-founder and CEO, Synthio Labs
“At Synthio, we’re building the AI infrastructure that makes that possible – intelligently, compliantly, and at scale.”
Rajashekar Vasantha, Co-founder and CTO, Synthio Labs
“We’re designing products that make every conversation between pharma and their customers smarter, faster, and more meaningful. Healthcare is moving into a world of abundance. Our view is simple: bring consumer-grade experiences to pharma and empower the people delivering care.”
Sahitya Sridhar, Co-founder and Chief Product Officer, Synthio Labs
“It’s been a pleasure working with the Synthio Labs team. They built a voice AI agent that engaged thousands of eczema patients, completing 5,000 calls in just two days. The agent supported onboarding, screening, and patient assistance end-to-end, fully automating our feedback and review collection. We’re very happy with the results and look forward to working together again.”
Rafal Pielak, Founder and CEO, Soteri Skin
